|
TW202122387A
(zh)
*
|
2019-09-12 |
2021-06-16 |
美商米瑞替療法公司 |
Mta協同性之prmt5抑制劑
|
|
US20240208912A1
(en)
*
|
2021-03-11 |
2024-06-27 |
Mirati Therapeutics, Inc. |
MTA-Cooperative PRMT5 Inhibitors
|
|
IL307393A
(en)
*
|
2021-04-08 |
2023-12-01 |
Mirati Therapeutics Inc |
Combination therapies used in PRMT5 inhibitors to treat cancer
|
|
IL307392A
(en)
*
|
2021-04-08 |
2023-12-01 |
Mirati Therapeutics Inc |
Combination therapies with PRMT5 inhibitors for cancer treatment
|
|
EP4347569A4
(en)
*
|
2021-06-02 |
2025-03-26 |
Ideaya Biosciences, Inc. |
Combination therapy comprising a mat2a inhibitor and a type ii prmt inhibitor
|
|
EP4412607A1
(en)
|
2021-10-06 |
2024-08-14 |
Mirati Therapeutics, Inc. |
Combination therapies using prmt5 inhibitors for the treatment of cancer
|
|
IL311707A
(en)
|
2021-10-06 |
2024-05-01 |
Mirati Therapeutics Inc |
Methods for the separation of enantiomers
|
|
US20260109709A1
(en)
|
2021-11-05 |
2026-04-23 |
Mirati Therapeutics, Inc. |
2-amino imidazole derivatives as prmt5 inhibitors
|
|
WO2023098439A1
(zh)
*
|
2021-11-30 |
2023-06-08 |
上海和誉生物医药科技有限公司 |
一种吡唑衍生物，其制备方法和在药学上的应用
|
|
EP4458812A1
(en)
*
|
2021-12-27 |
2024-11-06 |
Medshine Discovery Inc. |
Pyrazole-1(2h)-phthalazinone compound and application thereof
|
|
CN114315735B
(zh)
*
|
2021-12-29 |
2023-08-01 |
广州中医药大学(广州中医药研究院) |
一种鲁米诺酯化衍生物及其制备方法与应用
|
|
CN116903611A
(zh)
*
|
2022-01-26 |
2023-10-20 |
上海优理惠生医药有限公司 |
一种酞嗪酮类化合物、其制备方法、包含其药物组合物及其应用
|
|
EP4493555A4
(en)
*
|
2022-03-15 |
2026-03-25 |
Beone Medicines I Gmbh |
4-(AMINOMETHYL)-6-(1-METHYL-1H-PYRAZOL-4-YL)ISOQUINOLIN-1(2H)-ONE DERIVATIVES USED AS PRMT5 INHIBITORS COOPERATE WITH MTA
|
|
WO2023202626A1
(zh)
*
|
2022-04-22 |
2023-10-26 |
北京望实智慧科技有限公司 |
稠和哒嗪酮化合物作为prmt5抑制剂
|
|
CN117843634A
(zh)
*
|
2022-05-24 |
2024-04-09 |
上海美悦生物科技发展有限公司 |
Sik抑制剂及其组合物、制备方法和用途
|
|
CN116178347B
(zh)
*
|
2022-06-29 |
2025-07-04 |
苏州浦合医药科技有限公司 |
Prmt5-mta抑制剂
|
|
EP4574816A4
(en)
|
2022-07-07 |
2026-01-14 |
Xizang Haisco Pharmaceutical Co Ltd |
HETEROCYCLIC COMPOUND CAPABLE OF INHIBITING PRMT5 - MTA AND ITS USE
|
|
CN117430596A
(zh)
*
|
2022-07-13 |
2024-01-23 |
上海海和药物研究开发股份有限公司 |
二并环类mat2a抑制剂及其用途
|
|
CN119301101A
(zh)
*
|
2022-07-29 |
2025-01-10 |
四川科伦博泰生物医药股份有限公司 |
甲基吡唑化合物、包含其的药物组合物及其制备方法和用途
|
|
CN119585261A
(zh)
*
|
2022-08-02 |
2025-03-07 |
上海艾力斯医药科技股份有限公司 |
一种prmt5抑制剂、其制备方法及应用
|
|
CN119730853A
(zh)
|
2022-08-15 |
2025-03-28 |
阿斯利康(瑞典)有限公司 |
用于治疗癌症的mta协同prmt5抑制剂
|
|
CN119836290A
(zh)
|
2022-09-01 |
2025-04-15 |
米拉蒂治疗公司 |
使用prmt5抑制剂和bcl-2家族抑制剂治疗癌症的组合疗法
|
|
WO2024091551A1
(en)
*
|
2022-10-25 |
2024-05-02 |
Tango Therapeutics, Inc. |
Crystalline forms, pharmaceutical compositions and methods of use thereof
|
|
EP4628483A1
(en)
*
|
2022-11-29 |
2025-10-08 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Dihydrophthalazine-containing compound
|
|
WO2024173215A1
(en)
|
2023-02-13 |
2024-08-22 |
Mirati Therapeutics, Inc. |
Crystalline forms of 2-(4-(4-(aminomethyl)-1-oxo-1,2- dihydrophthalazin-6-yl)-1-methyl-1h- pyrazol-5-yl)-4-chloro-6-cyclopropoxy-3-fluorobenzonitrile
|
|
US20240270719A1
(en)
|
2023-02-13 |
2024-08-15 |
Mirati Therapeutics, Inc. |
Crystalline forms of 2-(4-(4-(aminomethyl)-1-oxo-1,2-dihydrophthalazin-6-yl)-1-methyl-1h-pyrazol-5-yl)-4-chloro-6-cyclopropoxy-3-fluorobenzonitrile
|
|
WO2024170488A1
(en)
|
2023-02-13 |
2024-08-22 |
Astrazeneca Ab |
Prmt5 inhibitor for use in cancer therapy
|
|
EP4665722A1
(en)
|
2023-02-13 |
2025-12-24 |
Mirati Therapeutics, Inc. |
Crystalline forms of 2-(4-(4-(aminomethyl)-1-oxo-1,2-dihydrophthalazin-6-yl)-1-methyl-1h-pyrazol-5-yl)-4-chloro-6-cyclopropoxy-3-fluorobenzonitrile
|
|
KR102818470B1
(ko)
*
|
2023-02-23 |
2025-06-10 |
한양대학교 산학협력단 |
신규한 아미노락톤 유도체 및 이의 신규한 제조방법
|
|
WO2024220917A1
(en)
|
2023-04-21 |
2024-10-24 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
CN121752566A
(zh)
*
|
2023-06-16 |
2026-03-27 |
中山优理生物医药有限公司 |
一种氨基吡啶类化合物、其制备方法、包含其药物组合物及其应用
|
|
WO2025016323A1
(zh)
|
2023-07-14 |
2025-01-23 |
江苏亚虹医药科技股份有限公司 |
蛋白质精氨酸酶甲基转移酶-5抑制剂及其医药用途
|
|
AU2024320474A1
(en)
|
2023-08-08 |
2026-03-26 |
Mirati Therapeutics, Inc. |
Methods and compositions for treating malignant peripheral nerve sheath tumors
|
|
AU2024319888A1
(en)
*
|
2023-08-09 |
2026-02-26 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Heteroaryl compound, preparation method therefor, and use thereof in medicine
|
|
WO2025059579A1
(en)
|
2023-09-15 |
2025-03-20 |
Ideaya Biosciences, Inc. |
Methods of treating mat2a related diseases
|
|
WO2025064286A1
(en)
*
|
2023-09-19 |
2025-03-27 |
Mirati Therapeutics, Inc. |
Stable 4-(aminomethyl)-6-(phenylpyrazolyl)phthalazinone compositions and processes for preparation thereof
|
|
AU2024344078A1
(en)
|
2023-09-20 |
2026-04-02 |
Ideaya Biosciences, Inc. |
Combination therapy with a parg inhibitor
|
|
WO2025061102A1
(zh)
*
|
2023-09-20 |
2025-03-27 |
西藏海思科制药有限公司 |
一种含氰基的杂环化合物及其用途
|
|
WO2025072544A1
(en)
|
2023-09-27 |
2025-04-03 |
Ideaya Biosciences, Inc. |
Sulfonamino indazole compounds as inhibitors of parg
|
|
WO2025068985A1
(en)
*
|
2023-09-28 |
2025-04-03 |
Beigene Switzerland Gmbh |
1-(1-oxo-1,2-dihydrophthalazin-6-yl)cycloalkyl-1-carboxamide derivatives as mta-cooperative inhibitors of prmt5
|
|
TW202532064A
(zh)
*
|
2023-11-28 |
2025-08-16 |
大陸商正大天晴藥業集團股份有限公司 |
含有雜環二氫酞嗪的化合物
|
|
WO2025180390A1
(zh)
*
|
2024-02-27 |
2025-09-04 |
烨辉医药科技(上海)有限公司 |
具有四环并环结构的mta协同性prmt5抑制剂化合物
|
|
WO2025212574A1
(en)
|
2024-04-02 |
2025-10-09 |
Mirati Therapeutics, Inc. |
Processes for preparation of prmt5 inhibitors and intermediates for making the same
|
|
WO2025217008A1
(en)
|
2024-04-08 |
2025-10-16 |
Mirati Therapeutics, Inc. |
Combination therapies using prmt5 inhibitors and sos1 inhibitors for the treatment of cancer
|
|
US20250312343A1
(en)
|
2024-04-08 |
2025-10-09 |
Mirati Therapeutics, Inc. |
Combination therapies using prmt5 inhibitors and kras g12d inhibitors for the treatment of cancer
|
|
WO2025217007A1
(en)
|
2024-04-08 |
2025-10-16 |
Mirati Therapeutics, Inc. |
Combination therapies using prmt5 inhibitors and immune checkpoint inhibitors for the treatment of cancer
|